Denosumab

Denosumab has been studied in 192 papers since 2016: 18 trials and 62 observational studies in people, 5 in animals, 94 reviews; 90 in the past year. It is an approved medicine. The newest story, Nov 11, 2026: “Bisphosphonates linked to more repeat fractures than denosumab”.

InterventionApproved 2010

192 papers study it134 findingsUpdated

MeSH

13 new papers in 30 daysSee all 185 papers on denosumab

At a glance

Human trials report increased bone mineral density and improved physical function with denosumab in osteoporosis; independent labs also report functional benefits in humans, but a trial shows no clear functional effect. Observational studies link denosumab with lower mortality after hip fracture surgery. Papers declare ties to its developer Amgen.

134 findings in 75 papers from 2016 to 2026, 14 of them since April 2026

Independent labs found the same change in mice and people. 44 independent labs in 17 countries; 153 trials, 1 about aging, 28 with no results posted.

“There were no statistically significant differences between the denosumab and placebo groups in terms of changes in appendicular lean mass adjusted for ALM/Height2, LELM, chair stand performance, SPPB scores, or gait speed”
Impact of denosumab on muscle health in older adults in long-term careBone2025doi:10.1016/j.bone.2025.117552

6 of its findings point the other way.

Mice and humans: replicated by independent labs. Cells: a single group. Worms or flies: nothing yet.
  • 44 independent labs in 17 countries
  • 6 findings against
  • 153 trials, 1 about aging, 28 with no results posted
  • Funders: National Natural Science Foundation of China and others
  • 21 of 110 findings with company ties
  • 74 of 153 trials sponsored by its developers
  • Human trial17
  • Humans59
  • Animals5
  • In silico5

13 studies gave denosumab to people and measured what changed.

What changedDesignPeopleSource

up: Improves physical functionscore 7 to score 10

down: Prevents vertebral fracture0 new fractures

down: Decreases painsevere pain 74.4% to 9.5%

Trial48 monthsBoth> 75Older adults; The oldest old; osteoporosisGeriatric Care, Jun 11, 2026

up: Improves physical functionscore 9 vs 7 at T0, p 0.05

Trial12 months10 peopleWomenmean age 72-73 yearsOlder adults; elderly breast cancer patients treated with aromatase inhibitorsGeriatric Care, Jun 11, 2026

up: Improves bite force238.63 ± 169.21 N to 523.78 ± 512.80 N (p = 0.0017)

Trialsix months38 peopleBothaverage age of 71.2 yearsOlder adults; osteoporosisClinical oral investigations, Feb 21, 2026

up: Improves bone mineral densityp = 0.005

up: Improves physical functionp = 0.012

Trial12-month51 peopleexcluding menover 50 years oldMiddle-aged and elderly women over 50 years old in China with primary osteoporosisiScience, Dec 19, 2025

down: Decreases synovitis

down: Decreases pain

up: Improves joint function

TrialSingle-arm clinical trial in knee OA patientsNature communications, Dec 17, 2025

What did studies of denosumab find?

62

Studies of denosumab measured 62 outcomes; the most studied are bone mineral density (7 studies), physical function (6) and bone mineral density (5).

Bone mineral density

upin humans7

7 studies
  1. Denosumab improves bone mineral density in Chinese osteoporosis patients (p = 0.005).

    “One-year outcome data analysis revealed that the denosumab group showed significantly greater improvements than the control group in bone mineral density (p = 0.005), dominant hand grip strength (p = 0.014), 6-m walk gait speed (p = 0.012), and 5 times sit-up time (p = 0.021).”

    Human trialin Chinese osteoporosis patients12-month

    Denosumab ameliorates muscle indices in Chinese osteoporosis patients through clinical and bioinformatic evidence of RANKL in sarcopenia

    iScience

  2. Denosumab improves bone mineral density in primary osteoporosis patients (p < 0.05).

    “12 months of denosumab treatment significantly improved bone mineral density”

    Human trialin primary osteoporosis patients12 monthsn = 103

    Denosumab ameliorates muscle indices in Chinese osteoporosis patients through clinical and bioinformatic evidence of RANKL in sarcopenia

    iScience

  3. Denosumab increases bone mineral density in humans (postmenopausal osteoporosis at high fracture risk) (+9.6% lumbar spine, +7.3% femoral neck, pall < 0.05).

    “Denosumab administration (treatment duration 43 months), lead to BMD improvement by + 9.6% at the lumbar spine and + 7.3% at the femoral neck (pall < 0.05).”

    Human trialpostmenopausal osteoporosis at high fracture risksubcutaneous injection60 mg subcutaneously every 6 months43 monthsfemalesn = 130

    Calf circumference predicts changes of bone mineral density in postmenopausal osteoporotic women receiving denosumab

    Aging clinical and experimental research

  4. Denosumab is linked with better bone mineral density in humans (especially in patients with T-scores higher than -2.5).

    “BMD improved more with denosumab than with zoledronic acid, especially in patients with T-scores higher than -2.5.”

    Humansespecially in patients with T-scores higher than -2.55 yearsmales

    Five-Year Outcomes of Continuous Treatment with Zoledronic Acid Versus Denosumab in Older Men with High Fracture Risk: Risk Factor Analysis of Bone Density Improvement and Incidence of New Fracture

    Journal of clinical pharmacology

  5. Denosumab is linked with higher bone mineral density in humans.

    “BMD significantly improved after 5 years of medication”

    Humans5 yearsmales

    Five-Year Outcomes of Continuous Treatment with Zoledronic Acid Versus Denosumab in Older Men with High Fracture Risk: Risk Factor Analysis of Bone Density Improvement and Incidence of New Fracture

    Journal of clinical pharmacology

  6. Denosumab increases bone mineral density in men.

    “Denosumab and anabolic agents increase BMD”

    Reviewin men

    Bone health in older men

    Maturitas

  7. Denosumab increases bone mineral density in osteoporosis.

    “Denosumab, a targeted anti-osteoporotic agent, mediates therapeutic effects by inhibiting bone resorption through the RANK-RANKL-OPG (RRO) pathway, consequently enhancing bone mineral density.”

    Reviewin osteoporosis

    Advances in the Study of Denosumab Treatment for Osteoporosis and Sarcopenia in the Chinese Middle-Aged and Elderly Population

    International journal of general medicine

  8. Denosumab improves bone mineral density in postmenopausal women and men.

    “Denosumab has been shown to improve bone mineral density”

    Reviewin postmenopausal women and men

    The use of denosumab in osteoporosis - an update on efficacy and drug safety

    Expert opinion on drug safety

  9. Denosumab improves bone mineral density in humans (compared with teriparatide, in women with postmenopausal osteoporosis) (MD -4.14, 95% CI -6.72 to -1.54 (radius); also hip MD -2.01 and one-third radius MD -3.63).

    “Denosumab showed better efficacy than teriparatide in improving radius BMD”

    Reviewcompared with teriparatide, in women with postmenopausal osteoporosisradiusfemalesn = 39,095

    Drug efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic acid for the treatment of postmenopausal osteoporosis: a network meta-analysis of randomized controlled trials

    European review for medical and pharmacological sciences

More on Bone mineral density

Physical function

upin humans5no changein humans1

6 studies
  1. Denosumab improves physical function in humans (osteoporosis) (score 7 to score 10).

    “4) SPPB score 10 (p 0.05) showing improvement in balance and gait rates.”

    Human trialosteoporosis60 mg48 months

    25 | Analytics in effectiveness of therapeutical compliance in elderly patients affected by bone frailty

    Geriatric Care

  2. Denosumab improves physical function in humans (elderly breast cancer patients treated with aromatase inhibitors) (score 9 vs 7 at T0, p 0.05).

    “At T 24 group A patients average SPPB score was 9 (p 0.05) showing an improvement in gait rate.”

    Human trialelderly breast cancer patients treated with aromatase inhibitorsn = 10

    23 | Analytics for adapted physical excercise effectiveness aimed at prevention of risk factors for osteoporosis and frailty in elderly patients affected by breast cancer

    Geriatric Care

  3. Denosumab improves physical function in Chinese osteoporosis patients (p = 0.012).

    “One-year outcome data analysis revealed that the denosumab group showed significantly greater improvements than the control group in bone mineral density (p = 0.005), dominant hand grip strength (p = 0.014), 6-m walk gait speed (p = 0.012), and 5 times sit-up time (p = 0.021).”

    Human trialin Chinese osteoporosis patients12-month

    Denosumab ameliorates muscle indices in Chinese osteoporosis patients through clinical and bioinformatic evidence of RANKL in sarcopenia

    iScience

  4. Denosumab improves physical function in primary osteoporosis patients (p < 0.05).

    “12 months of denosumab treatment significantly improved bone mineral density, grip strength, 6-m walk gait speed, 5 times sit-up time, and Timed Up and Go (TUG) test”

    Human trialin primary osteoporosis patients12 monthsn = 103

    Denosumab ameliorates muscle indices in Chinese osteoporosis patients through clinical and bioinformatic evidence of RANKL in sarcopenia

    iScience

  5. Denosumab improves physical function.

    “Improvements in muscle function were observed in 6-m walk gait speed (1.01±0.16 m/s; 95% CI:–0.20 to–0.06; P < 0.001), 5 times sit-up time (12.14±2.98 s; 95% CI: 1.22 to 5.30; P = 0.020), and TUG (9.48±2.33 s; 95% CI: 0.38 to 2.64; P = 0.010), as shown in.”

    Human trialone-year treatment coursen = 40

    Denosumab for Primary Osteoporosis and Its Impact on Sarcopenia in the Chinese Population: Insights from Clinical Evidence and RANKL Pathway Mendelian Randomization

    Clinical interventions in aging

  6. Denosumab improves physical function in humans (P < 0.05).

    “improved muscle function after 6 months”

    Human trial6 months

    Denosumab for Primary Osteoporosis and Its Impact on Sarcopenia in the Chinese Population: Insights from Clinical Evidence and RANKL Pathway Mendelian Randomization

    Clinical interventions in aging

  7. Denosumab showed no clear effect on physical function in humans.

    “The findings did to materially change in exploratory analyses combining both men and women nor did we observe consistent differential treatment effects in subgroup analyses with respect to baseline osteoporosis, muscle mass and function, fall history and comorbid burden.”

    Human trial2 yearsn = 201

    Impact of denosumab on muscle health in older adults in long-term care

    Bone

  8. Denosumab is linked with better physical function in patients with low BMD, compared to bisphosphonates (+8.2 ± 14.4% vs +0.9 ± 8.6%, p = 0.03).

    “The Dmab group showed a significantly higher increase in chair rising test force compared to the BP group”

    Humansin patients with low BMD, compared to bisphosphonates17.6 ± 9.0 months

    Beneficial effects of denosumab on muscle performance in patients with low BMD: a retrospective, propensity score-matched study

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

Bone mineral density

upin humans5

5 studies
  1. Denosumab increases bone mineral density.

    “At the one-year mark, lumbar spine bone mineral density showed significant improvement (T-score:–2.61±0.83; 95% CI:–0.87 to–0.16; P = 0.007).”

    Human trialone-year treatment coursen = 15

    Denosumab for Primary Osteoporosis and Its Impact on Sarcopenia in the Chinese Population: Insights from Clinical Evidence and RANKL Pathway Mendelian Randomization

    Clinical interventions in aging

  2. Denosumab increases bone mineral density in humans (P < 0.05).

    “with further gains in bone mineral density and muscle strength observed at 1 year (all P < 0.05)”

    Human trial1 year

    Denosumab for Primary Osteoporosis and Its Impact on Sarcopenia in the Chinese Population: Insights from Clinical Evidence and RANKL Pathway Mendelian Randomization

    Clinical interventions in aging

  3. Denosumab increases bone mineral density in humans (+1.9% vs. -3.3% radius; +1.4% vs. -4.5% tibia; p<0.01).

    “DMAB participants had an increase in total volumetric BMD at both anatomic sites, while the PBO participants had a decrease (+1.9% vs. -3.3% radius; +1.4% vs. -4.5% tibia; between-group difference p<0.01 for both).”

    Human trialbone18 monthsn = 36

    SAT-721 Denosumab After Bariatric Surgery Increases Bone Mass, Microarchitecture, and Estimated Strength in Postmenopausal Women and Older Men: A Randomized Controlled Trial

    ENDO 2025 abstract

  4. Denosumab increases bone mineral density in humans (osteoporosis).

    “improving bone density”

    Human trialosteoporosis60 mg2 years

    Impact of denosumab on muscle health in older adults in long-term care

    Bone

  5. Denosumab is linked with better bone mineral density in humans (postmenopausal RA patients on long-term oral glucocorticoids) (0.444% greater gain, P=0.025).

    “Denosumab produced a significantly greater lumbar spine aBMD gain than alendronate (between-group difference: 0.444%, P=0.025).”

    Humanspostmenopausal RA patients on long-term oral glucocorticoidslumbar spineone year

    Comparison of the effects of denosumab and alendronate on fracture risk and bone metabolism in postmenopausal rheumatoid arthritis patients treated with oral glucocorticoids: A propensity score-matched retrospective cohort study

    Therapeutic advances in musculoskeletal disease

  6. Denosumab is linked with higher bone mineral density in humans (SONK patients undergoing UKA; denosumab plus supplements versus supplements only).

    “At 24 months, Group B had lower CTX but higher T-scores and BMD.”

    HumansSONK patients undergoing UKA; denosumab plus supplements versus supplements only60 mg every 6 months24 months

    A predictive nomogram for treatment response in osteonecrosis patients receiving denosumab with UKA: integrating bone turnover markers and functional parameters

    Endocrine connections

Grip strength

upin humans5

5 studies
  1. Denosumab improves grip strength in humans.

    “all 3 patients demonstrated marked improvements in pain scores (Visual Analog Scale, VAS), grip strength, and joint imaging after one year of follow-up.”

    Human trialin aromatase inhibitor-associated musculoskeletal syndrome, combined with slow-jogging aerobic exerciseone yearfemalesn = 3

    Denosumab and Slow-Jogging Aerobic Exercise in Aromatase Inhibitor-Associated Musculoskeletal Syndrome: A Case Series

    American journal of physical medicine & rehabilitation

  2. Denosumab is linked with better grip strength in humans (postmenopausal osteoporosis) (p = 0.026).

    “Nondominant handgrip strength was the only grip parameter showing a significant between-group difference (p = 0.026), mainly due to higher values in denosumab-treated patients than in untreated osteoporotic patients”

    Humanspostmenopausal osteoporosisfemales

    Comparison of Denosumab and Bisphosphonates for Sarcopenia in Postmenopausal Osteoporosis

    Journal of clinical medicine

  3. Denosumab is linked with better grip strength in patients with low BMD (+5.1 ± 25.5% vs -6.1 ± 10.2%, p < 0.001).

    “a significantly higher increase in grip force in both the Dmab (p < 0.001) and BP group (p = 0.001) compared to the vitamin D group was observed”

    Humansin patients with low BMD17.6 ± 9.0 monthsn = 150

    Beneficial effects of denosumab on muscle performance in patients with low BMD: a retrospective, propensity score-matched study

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

  4. Denosumab improves grip strength in humans (compared with bisphosphonates or placebo).

    “Most reported favorable outcomes for denosumab compared to bisphosphonates or placebo, particularly in grip strength and physical performance.”

    Reviewcompared with bisphosphonates or placebo

    Beyond bone effects: the role of denosumab in muscle Health - A systematic review

    Aging clinical and experimental research

  5. Denosumab improves grip strength in humans.

    “It enhanced muscular function by improving appendicular lean mass and grip strength while reducing fall risk.”

    Review

    Beyond Bone Remodeling: Denosumab's Multisystemic Benefits in Musculoskeletal Health, Metabolism, and Age-Related Diseases-A Narrative Review

    Biomedicines

Pain

downin humans3downin animals1no changein humans1

5 studies
  1. Denosumab decreases pain in humans (osteoporosis) (severe pain 74.4% to 9.5%).

    “NRS: 37.3% mild pain (p<0.01), 28.1% moderate pain (p<0.01), 9.5% severe pain (p<0.01)”

    Human trialosteoporosis60 mg48 months

    25 | Analytics in effectiveness of therapeutical compliance in elderly patients affected by bone frailty

    Geriatric Care

  2. Denosumab decreases pain in humans (single-arm clinical trial in knee OA patients; VAS score).

    “shows that denosumab alleviates synovitis and pain, improving joint function in knee OA patients”

    Human trialsingle-arm clinical trial in knee OA patients; VAS score

    Denosumab attenuates knee osteoarthritis progression by inhibiting synovial inflammation via the RANK/TRAF6/FSTL1 signalling

    Nature communications

  3. Denosumab is linked with lower pain in humans (SONK patients undergoing UKA; denosumab plus supplements versus supplements only) (VAS: T = 1.11, P = 0.04).

    “Group B showed significantly better HSS scores (T = 15.07, P = 0.04), VAS scores (T = 1.11, P = 0.04)”

    HumansSONK patients undergoing UKA; denosumab plus supplements versus supplements onlyknee60 mg every 6 months24 months

    A predictive nomogram for treatment response in osteonecrosis patients receiving denosumab with UKA: integrating bone turnover markers and functional parameters

    Endocrine connections

  4. Denosumab was not clearly linked with pain in postmenopausal osteopenic early breast cancer patients on aromatase inhibitors (T1 4.36 vs baseline 4.76, p=0.12).

    “compared to denosumab (T1 4.36 vs baseline 4.76, p=0.12)”

    Humansin postmenopausal osteopenic early breast cancer patients on aromatase inhibitorsbone60 mg18 monthsfemales

    The role of bone modifying agents for secondary osteoporosis prevention and pain control in post-menopausal osteopenic breast cancer patients undergoing adjuvant aromatase inhibitors

    Frontiers in endocrinology

  5. Denosumab decreases pain in rodent and canine osteoarthritis models.

    “significantly reducing synovial inflammation, cartilage erosion, and pain compared with systemic administration”

    Animalsin rodent and canine osteoarthritis modelsdissolvable microneedle array (MNs@De)knee joint

    Dissolvable microneedles loaded with denosumab alleviate knee osteoarthritis in rodent and canine models by inhibiting macrophage senescence

    Theranostics

Bone turnover markers

downin humans2

2 studies
  1. Denosumab decreases bone turnover markers.

    “After six months of denosumab treatment, significant reductions were observed in bone turnover markers compared to baseline: t-PINP (16.83±13.03 ng/mL; 95% CI: 33.89 to 45.71; P < 0.001), N-terminal mid-fragment osteocalcin (15.66±4.57 ng/mL; 95% CI: 6.64 to 14.48; P < 0.001), and β-CTx (0.14±0.05 ng/mL; 95% CI: 0.15 to 0.26; P < 0.001”

    Human trialone-year treatment coursen = 40

    Denosumab for Primary Osteoporosis and Its Impact on Sarcopenia in the Chinese Population: Insights from Clinical Evidence and RANKL Pathway Mendelian Randomization

    Clinical interventions in aging

  2. Denosumab decreases bone turnover markers in humans (P < 0.05).

    “Denosumab significantly reduced bone turnover markers”

    Human trial6 months

    Denosumab for Primary Osteoporosis and Its Impact on Sarcopenia in the Chinese Population: Insights from Clinical Evidence and RANKL Pathway Mendelian Randomization

    Clinical interventions in aging

  3. Denosumab decreases bone turnover markers in individuals at risk of fracture.

    “antiresorptive agents such as bisphosphonates and denosumab cause rapid alterations in BTMs, which correlate with long-term gains in BMD and reduced fracture risk.”

    Reviewin individuals at risk of fracture

    Clinical Significance of Bone Turnover Markers in Osteoporosis: Fracture Risk Assessment and Treatment Monitoring

    Journal of menopausal medicine

More on Bone turnover markers

Vertebral fracture

downin humans1no changein humans1

2 studies
  1. Denosumab prevents vertebral fracture in humans (osteoporosis) (0 new fractures).

    “AT T48,through X rays of the spine in the dorsal,lumbar and sacral regions,we checked that no new fractures had occurred.”

    Human trialosteoporosis60 mg48 months

    25 | Analytics in effectiveness of therapeutical compliance in elderly patients affected by bone frailty

    Geriatric Care

  2. Denosumab was not clearly linked with vertebral fracture in humans Under androgen deprivation therapies; compared with bisphosphonates (No significant difference; P = .423).

    “without significant difference between denosumab and bisphosphonate treatment (P = .423)”

    HumansUnder androgen deprivation therapies; compared with bisphosphonatesmales

    Effectiveness of Bisphosphonates and Denosumab on Risk of Vertebral Fractures in Prostate Cancer Patients Under Androgen Deprivation Therapies: A Real-World Prospective Study

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

More on Vertebral fracture

Mortality

downin humans1no changein humans1HR 0.45

2 studies
  1. Denosumab is linked with lower mortality in humans following primary osteoporotic hip fracture surgery (HR = 0.45).

    “A lower mortality rate was observed in patients in the denosumab group compared to the control group within three years postoperatively (HR = 0.45, p = 0.001).”

    Humansfollowing primary osteoporotic hip fracture surgery3 years

    Treatment effects of denosumab on refracture and mortality in elderly patients following primary osteoporotic hip fracture surgery: real-world data from a retrospective observational study

    Annals of medicine

  2. Denosumab was not clearly linked with mortality in humans (fragility hip fracture) (p = 0.730).

    “Denosumab use was not associated with reduced mortality(p = 0.730), even after multiple doses (p = 0.890).”

    Humansfragility hip fracturen = 738

    Risk of all-cause mortality in elderly patients with hip fractures treated with denosumab

    Research SquarePreprint

Cellular senescence

downin animals1downin mice1

2 studies
  1. Denosumab decreases cellular senescence in mice (age-related OA-OP).

    “reduced chondrocyte and BMSC senescence.”

    Animalsage-related OA-OP

    Denosumab-functionalized nanoparticles target macrophages to mitigate age-related osteoarthritis and osteoporosis

    Journal of materials chemistry. B

  2. Denosumab inhibits cellular senescence in osteoarthritis models.

    “Single-cell profiling revealed that denosumab markedly decreased senescent macrophage abundance within synovial tissue.”

    Animalsin osteoarthritis modelssynovial tissue

    Dissolvable microneedles loaded with denosumab alleviate knee osteoarthritis in rodent and canine models by inhibiting macrophage senescence

    Theranostics

More on Cellular senescence

Appendicular lean mass

no changein humans1upin humans1

2 studies
  1. Denosumab showed no clear effect on appendicular lean mass in humans.

    “The findings did to materially change in exploratory analyses combining both men and women nor did we observe consistent differential treatment effects in subgroup analyses with respect to baseline osteoporosis, muscle mass and function, fall history and comorbid burden.”

    Human trial2 yearsn = 201

    Impact of denosumab on muscle health in older adults in long-term care

    Bone

  2. Denosumab is linked with higher appendicular lean mass in humans (osteoporotic women, compared with no treatment).

    “denosumab over 3 years improved appendicular lean mass and handgrip strength compared to no treatment”

    Humansosteoporotic women, compared with no treatment3 yearsfemales

    RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass

    The Journal of clinical investigation

More on Appendicular lean mass

Trabecular bone score

upin humans2

2 studies
  1. Denosumab improves trabecular bone score in humans (older women with non-metastatic breast cancer undergoing adjuvant endocrine therapy).

    “Significant improvements in TBS at the lumbar spine, RSMI and whole-body composition (arms, legs, and trunk) were observed in the denosumab group compared with the BF group.”

    Human trialolder women with non-metastatic breast cancer undergoing adjuvant endocrine therapylumbar spine60 mg every 6 months vs alendronate 70 mg/weekone yearfemalesn = 60

    Aromatase inhibitor-induced bone loss osteosarcopenia in older patients with breast cancer: effects of the RANK/RANKL system's inhibitor denosumab vs. bisphosphonates

    Internal and emergency medicine

  2. Denosumab increases trabecular bone score in humans (osteoporosis).

    “TBS has been shown to increase with anabolic therapy and to a lesser degree with denosumab.”

    Reviewosteoporosis

    Utility of Trabecular Bone Score in the Management of Patients with Osteoporosis

    Endocrinology and metabolism clinics of North America

More on Trabecular bone score

Synovitis

downin humans1downin mice1

1 study
  1. Denosumab decreases synovitis in humans (single-arm clinical trial in knee OA patients).

    “shows that denosumab alleviates synovitis and pain, improving joint function in knee OA patients”

    Human trialsingle-arm clinical trial in knee OA patientssynovium

    Denosumab attenuates knee osteoarthritis progression by inhibiting synovial inflammation via the RANK/TRAF6/FSTL1 signalling

    Nature communications

  2. Denosumab decreases synovitis in mice (RANK/TRAF6/FSTL1 signalling; post-traumatic, inflammatory and aged murine OA models).

    “effectively reduces synovitis through RANK/TRAF6/FSTL1 signalling in post-traumatic, inflammatory, and aged OA murine models”

    AnimalsRANK/TRAF6/FSTL1 signalling; post-traumatic, inflammatory and aged murine OA modelssynovium

    Denosumab attenuates knee osteoarthritis progression by inhibiting synovial inflammation via the RANK/TRAF6/FSTL1 signalling

    Nature communications

More on Synovitis

Bone failure load

no changein humans1upin humans1+3%

1 study
  1. Denosumab showed no clear effect on bone failure load in humans (compared with alendronate).

    “However, estimated strength did not differ between denosumab and alendronate treated groups.”

    Human trialcompared with alendronate12 monthsfemales

    The effect of denosumab and alendronate on trabecular plate and rod microstructure at the distal tibia and radius: A post-hoc HR-pQCT study

    Bone

  2. Denosumab increases bone failure load in humans (postmenopausal) (+3.0%).

    “improvements using denosumab was significant compared to placebo (stiffness: p = 0.004; failure load: p = 0.003).”

    Human trialpostmenopausaltibia12 monthsfemalesn = 72

    The effect of denosumab and alendronate on trabecular plate and rod microstructure at the distal tibia and radius: A post-hoc HR-pQCT study

    Bone

More on Bone failure load

Visual analog scale

downin humans1

1 study
  1. Denosumab decreases visual analog scale in humans.

    “all 3 patients demonstrated marked improvements in pain scores (Visual Analog Scale, VAS), grip strength, and joint imaging after one year of follow-up.”

    Human trialin aromatase inhibitor-associated musculoskeletal syndrome, combined with slow-jogging aerobic exerciseone yearfemalesn = 3

    Denosumab and Slow-Jogging Aerobic Exercise in Aromatase Inhibitor-Associated Musculoskeletal Syndrome: A Case Series

    American journal of physical medicine & rehabilitation

More on Visual analog scale

Bite force

upin humans1

1 study
  1. Denosumab improves bite force in humans (osteoporosis) (238.63 ± 169.21 N to 523.78 ± 512.80 N (p = 0.0017)).

    “Mean bite force increased from 238.63 ± 169.21 N to 523.78 ± 512.80 N after six months of denosumab.”

    Human trialosteoporosissix monthsn = 38

    The effect of osteoporosis medication on bite force in older adults: a prospective clinical study

    Clinical oral investigations

All 62

What is denosumab linked with?

27

Studies link denosumab with 27 measures, among them type 2 diabetes, fracture risk and mortality.

Type 2 diabetes

downin humans3HR 0.73–0.78

3 studies
  1. Denosumab is linked with a lower risk of type 2 diabetes in humans (anti-osteoporotic treatment-naive users in primary care, comparator alendronate) (HR: 0.73; 0.58-0.89).

    “Denosumab was associated with a reduced risk of T2DM compared to alendronate, adjusting for age, sex, index year, visits, obesity, comorbidities and statins (HR: 0.73; 0.58-0.89).”

    Humansanti-osteoporotic treatment-naive users in primary care, comparator alendronate

    Type 2 diabetes incidence in patients initiating denosumab or alendronate treatment: a primary care cohort study

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

  2. Denosumab lowers the risk of type 2 diabetes in osteoporotic patients (HR = 0.78, 95% CI 0.70, 0.87, -22%).

    “Results revealed a 22% reduction in T2D incidence with denosumab (HR = 0.78, 95% CI 0.70, 0.87, p<0.00001, I2= 62%)”

    Reviewin osteoporotic patients

    Denosumab's Role in Reducing Type 2 Diabetes Risk and Improving Glycaemic Control in Osteoporotic Patients - A Meta-analysis

    Malaysian orthopaedic journal

  3. Denosumab lowers the risk of type 2 diabetes in humans.

    “Notably, denosumab use was associated with reduced Type II diabetes mellitus risk through improved glucose metabolism.”

    Review

    Beyond Bone Remodeling: Denosumab's Multisystemic Benefits in Musculoskeletal Health, Metabolism, and Age-Related Diseases-A Narrative Review

    Biomedicines

More on Type 2 diabetes

Fracture risk

downin humans3

3 studies
  1. Denosumab lowers the risk of fracture risk in humans (Patients with rheumatic diseases).

    “Timely dual-energy X-ray absorptiometry (DXA) and anti-osteoporotic therapy (bisphosphonates, denosumab) can reduce fracture risk.”

    ReviewPatients with rheumatic diseases

    Osteoporosis in Rheumatic Diseases as a Risk Factor for Pathological Fractures

    Byulleten nauki i praktiki

  2. Denosumab lowers the risk of fracture risk in elderly and frail populations.

    “Compared to bisphosphonates, denosumab demonstrated superior outcomes in bone mineral density improvement and fracture risk reduction”

    Reviewin elderly and frail populations

    Beyond Bone Remodeling: Denosumab's Multisystemic Benefits in Musculoskeletal Health, Metabolism, and Age-Related Diseases-A Narrative Review

    Biomedicines

  3. Denosumab lowers the risk of fracture risk in humans (Compared with oral bisphosphonates).

    “Zoledronate, denosumab and anabolic therapy are associated with a higher fracture risk reduction than oral bisphosphonates.”

    ReviewCompared with oral bisphosphonates

    Which treatment to prevent an imminent fracture?

    Bone reports

Mortality

downin humans3HR 0.52–0.86

3 studies
  1. Denosumab is associated with mortality in humans (fracture cohort; compared with no treatment) (48% lower mortality; HR 0.52, 95% CI 0.36–0.72).

    “Dmab was associated with 48% lower mortality in women”

    Humansfracture cohort; compared with no treatmentfemales

    Denosumab and Mortality in a Real-World Setting: A Comparative Study

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

  2. Denosumab is linked with a lower risk of mortality in humans after hip fracture surgery (HR: 0.60, 95% CI: 0.57 ~ 0.64).

    “Compared with a > 7-month drug interval for denosumab, an interval of ≤ 7 months led to lower all-cause mortality risk (hazard ratio (HR): 0.60, 95% confidence interval (CI): 0.57 ~ 0.64).”

    Humansafter hip fracture surgery

    Drug adherence and treatment duration for denosumab and mortality risk among hip fracture patients

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

  3. Denosumab is associated with mortality in humans Following osteoporotic fracture; compared with raloxifene and bazedoxifene (HR 0.86; 95% CI, 0.81–0.91).

    “denosumab (HR 0.86; 95% CI, 0.81-0.91)”

    HumansFollowing osteoporotic fracture; compared with raloxifene and bazedoxifeneMean follow-up of 4.73 years80.0% femalesn = 46,729

    Comparisons Between Different Anti-osteoporosis Medications on Postfracture Mortality: A Population-Based Study

    The Journal of clinical endocrinology and metabolism

Incident fragility fracture

no changein humans1

1 study
  1. Denosumab is associated with incident fragility fracture in humans (MONA syndrome and osteoporosis; treatment following romosozumab) (No incident fragility fractures during 18 months).

    “During the subsequent 18-month treatment with denosumab, no incident fragility fractures occurred.”

    HumansMONA syndrome and osteoporosis; treatment following romosozumabbone18 monthsfemales

    Significant bone mineral density improvement following sequential Romosozumab-Denosumab therapy in a postmenopausal woman with Multicentric Osteolysis, Nodulosis, and Arthropathy (MONA) syndrome

    Frontiers in endocrinology

More on Incident fragility fracture

Transition to a lower estimated fracture risk category

upin humans1OR 4.21

1 study
  1. Denosumab predicts transition to a lower estimated fracture risk category in humans (OR 4.21; p = 0.003; transition rates 79.5% versus 29.6% with bisphosphonates).

    “Multivariable logistic regression identified denosumab therapy (OR = 4.21, p = 0.003)”

    Humanspostmenopausal and senile osteoporosis; adjusted for baseline patient characteristics and treatment type36 monthsn = 298

    Baseline characteristics and bone mineral density changes associated with lower fracture risk in osteoporosis: a retrospective cohort study

    Rheumatology international

OPG/sRANKL ratio

upin humans1

1 study
  1. Denosumab is associated with OPG/sRANKL ratio in humans (Compared with zoledronic acid) (2.503 [2.053, 3.429] vs. 0.807 [0.549, 0.994]).

    “The OPG/sRANKL ratio increased more strongly at 12 months (2.503 [2.053, 3.429] vs. 0.807 [0.549, 0.994], p < 0.001).”

    HumansCompared with zoledronic acid12 monthsfemalesn = 186

    Denosumab linked to greater grip strength gains in women

    Journal of cachexia, sarcopenia and muscle

More on OPG/sRANKL ratio

Sarcopenia prevalence

downin humans1

1 study
  1. Denosumab is associated with sarcopenia prevalence in humans (52.1% vs. 69.8%, 30.2% vs. 50.7%, and 20.0% vs. 46.0% at 12, 24, and 36 months).

    “Sarcopenia prevalence was lower with denosumab at 12, 24 and 36 months”

    HumansStudy-defined sarcopenia based on an AWGS 2025-informed framework; compared with zoledronic acid12, 24 and 36 monthsfemalesn = 186

    Denosumab linked to greater grip strength gains in women

    Journal of cachexia, sarcopenia and muscle

More on Sarcopenia prevalence

Appendicular skeletal muscle mass index

upin humans1

1 study
  1. Denosumab is associated with appendicular skeletal muscle mass index in humans (Postmenopausal osteoporosis and prescreened sarcopenia risk; compared with zoledronic acid) (36-month change: 0.192 ± 0.059 vs. 0.089 ± 0.050 kg/m2).

    “ASMI did not differ at 12 months (p = 0.119) but favoured denosumab at 24 and 36 months”

    HumansPostmenopausal osteoporosis and prescreened sarcopenia risk; compared with zoledronic acidskeletal muscle36 monthsfemalesn = 186

    Denosumab linked to greater grip strength gains in women

    Journal of cachexia, sarcopenia and muscle

Grip strength

upin humans1

1 study
  1. Denosumab is associated with grip strength in humans (Postmenopausal osteoporosis and prescreened sarcopenia risk; compared with zoledronic acid) (36-month change: 2.52 ± 0.63 versus 0.99 ± 0.45 kg).

    “Denosumab showed greater functional improvement than zoledronic acid.”

    HumansPostmenopausal osteoporosis and prescreened sarcopenia risk; compared with zoledronic acid36 monthsfemalesn = 186

    Denosumab linked to greater grip strength gains in women

    Journal of cachexia, sarcopenia and muscle

Severe hypocalcemia

upin humans1

1 study
  1. Denosumab raises the risk of severe hypocalcemia in humans (chronic kidney disease).

    “addition of a black-boxed warning for severe hypocalcemia with denosumab in chronic kidney disease.”

    Reviewchronic kidney disease

    Updates in osteoporosis medications: maximizing benefits and minimizing risks

    American journal of medicine open

More on Severe hypocalcemia

All 27

Has denosumab been tested in people?

1 of 153 about aging

Yes: 18 trials and 62 observational studies in people have been published, and 150 trials are registered.

About aging

Approved

  • EMA Prolia

    May 26, 2010Osteoporosis, Postmenopausal, Osteoporosis, Osteoporosis in Postmenopausal Women, bone loss

  • FDA Prolia, Xgeva

    Jun 1, 2010Osteoporosis, Glucocorticoid-induced Osteoporosis, bone loss, postmenopausal women with osteoporosis, osteoporosis in men

  • EMA Xgeva

    Jul 13, 2011Giant Cell Tumor of Bone

  • FDA Jubbonti, Wyost

    Mar 5, 2024Osteoporosis, Glucocorticoid-induced Osteoporosis, bone loss, postmenopausal women with osteoporosis, osteoporosis in men

  • EMA Jubbonti

    May 16, 2024Osteoporosis, Osteoporosis, Postmenopausal, Osteoporosis in Postmenopausal Women, bone loss

  • EMA Wyost

    May 17, 2024Giant Cell Tumor of Bone

40 of 45

Repurposing

40 of 73

Every condition in trials

  • Prostatic neoplasm

    Phase 3Results posted5 trials

  • Castrate resistant prostate cancer

    Phase 3Results posted1 trial

  • Glucocorticoid induced ostepor steroid induced osteopor

    Phase 3Results posted1 trial

  • Health condition 1: M810- age-related osteoporosis without current pathological fracture

    Phase 3Recruiting1 trial

  • Aneurysmal Bone Cysts

    Phase 2Status unknown2 trials

  • Fibrous Dysplasia of Bone

    Phase 2Completed2 trials

All 10

Stopped

  • NCT02792413TerminatedOsteoporosis

    Modified study and new deposit in RECHMPL21\_0451

  • NCT03029442TerminatedOsteoporosis

    Study ended early due to COVID-19

  • NCT01558115TerminatedMetabolic bone disease

    Poor enrollment

  • NCT01077154TerminatedBreast neoplasm

    Terminated: Amgen decision following Primary Analysis. Not due to safety reason

  • NCT02051218TerminatedBreast neoplasm

    Board decision as by March 2026, the number of patients undergoing treatment decreased to around 50, from the total 1,380 patients enrolled in the trial. And due to price changes in medication

  • NCT02352753TerminatedOsteogenesis imperfecta

    The study was stopped earlier than planned due to safety concerns about high levels of calcium in the blood of the participants

All 11

Who is developing denosumab?

3 companies: Amgen, Shanghai Biomabs Pharmaceutical and CuraTeQ Biologics Private.

Companies
  • AmgenPhase 4glucocorticoid-induced osteoporosis, osteoporosis
  • Shanghai Biomabs PharmaceuticalPhase 3postmenopausal osteoporosis
  • CuraTeQ Biologics PrivatePhase 3health condition 1: M810- age-related osteoporosis without current pathological fracture

Trial sponsors

Funding

5 grants since 2018

National Health and Medical Research CouncilA$2.6MMedical Research Future FundA$1.9MDepartment of Health, Australian GovernmentA$1.9M

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    In humans, denosumab increases lumbar spine bone mineral density in postmenopausal women with rheumatoid arthritis taking long-term oral glucocorticoids; reviews report no muscle mass or strength benefit in long-term care. Of 153 registered trials, 31 ended over a year ago without posted results or citing papers; 82 are sponsored by its developers.

  2. Summary written from the findings.

Latest

Dec 2025: 8Jan 2026: 10Feb 2026: 8Mar 2026: 7Apr 2026: 5May 2026: 3Jun 2026: 7Jul 2026: 5Aug 2026: 5Sep 2026: 9Oct 2026: 8Nov 2026: 681 papers in 12 months
Journal of Bone Oncology

Calcium, vitamin D not tied to less bone loss on aromatase inhibitors

Over five years, spine bone density fell 11.1% with calcium and vitamin D and 11.4% without supplements in postmenopausal women taking breast cancer hormone therapy.Over five years, spine bone density fell 11.1% with calcium and vitamin D and 11.4% without supplements in postmenopausal women taking breast cancer hormone therapy.

Cohort · 636 peopleBone loss
JAMA Network Open

Bisphosphonates linked to more repeat fractures than denosumab

Women starting bisphosphonates had 52.7 repeat fractures per 1,000 person-years, versus 46.5 with denosumab, during three years of follow-up.Women starting bisphosphonates had 52.7 repeat fractures per 1,000 person-years, versus 46.5 with denosumab, during three years of follow-up.

Cohort studyBones and joints
Journal of Bone and Mineral Research

Delayed follow-up osteoporosis drugs linked to more hip fractures

Among 8,893 patients, high adherence to teriparatide was linked to a 20% lower relative hip fracture risk than lower adherence.Among 8,893 patients, high adherence to teriparatide was linked to a 20% lower relative hip fracture risk than lower adherence.

Cohort · 8,893 peopleHip fracture
Diabetes & Metabolism

Diabetes risk did not clearly differ between osteoporosis drugs

The hazard ratio for type 2 diabetes, comparing risk over time, was 0.93 for romosozumab versus denosumab, with no statistically clear difference.The hazard ratio for type 2 diabetes, comparing risk over time, was 0.93 for romosozumab versus denosumab, with no statistically clear difference.

See all 185 papers on denosumab